The company offers its mortgage loans in 50 states through the internet, national television and other marketing channels. It also offers title insurance, property valuation and settlement services; online marketing and lead generation services; online-based personal loans; and car sales support services to car rental and online car purchasing platforms.
Rocket Companies also operates a digital platform for buying and selling homes; a sales and support platform that offers inbound and outbound contact center services; and a loan origination platform.
Citigroup has the highest price target at $35, while the consensus target is $28. The shares were last seen trading at $30.71, up almost 10% on Tuesday.
This is a solid idea for more conservative investors looking at recent IPO action. Royalty Pharma PLC. (NASDAQ: RPRX) operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. The company engages in the identification, evaluation and acquisition of attractive royalties and royalty-related assets on various biopharmaceutical therapies. It collaborates with innovators from academic institutions, research hospitals, small and mid-cap biotechnology companies and pharmaceutical companies.
The company’s portfolio includes royalties on approximately 45 commercial products and four development-stage product candidates. It has royalties on various therapeutic areas and drug classes, including the following:
- Neulasta, Neupogen, Rituxan, Ibrance, Imbruvica, Trodelvy, Tazverik and Xtandi in oncology
- Lyrica in neuropathic pain
- Biktarvy, Genvoya, Prezista, Symtuza, Truvada and Atripla in HIV
- Humira, Remicade and Cimzia TNF inhibitors
- Kalydeco, Orkambi, Symdeko and Trikafta in cystic fibrosis
- Tecfidera and Tysabri in multiple sclerosis
- Emgality, Nurtec ODT and vazegepant in migraine
The $56 Truist Securities price target is a Wall Street high. The $52.21 consensus target is also well above the most recent close at $41.60 per share.
This company has backed up substantially since a red-hot start. Zoominfo Technologies Inc. (NASDAQ: ZI) operates a cloud-based go-to-market intelligence platform for information and insights on organizations and professionals in the United States and internationally.
The company’s platform helps sales and marketing professionals to identify the target customers, pinpoint the right decision-makers, obtain continually updated predictive lead and company scoring, monitor buying signals and other attributes of target companies, craft the right message, engage via automated sales tools, and track progress through the deal cycle.
Zoominfo customers operate in various industry verticals, including software, business services, manufacturing, telecommunications, financial services and insurance, retail, media and internet, transportation, education, hospitality, health care, and real estate, as well as global enterprises, mid-market companies and small and medium-sized business.
BofA Securities has a $60 price objective, which is tied for the highest on Wall Street. The consensus target is $53.79, and the last trade Tuesday hit the tape at $38.42.
All these recently public companies still offer aggressive investors outstanding entry levels, but most have not seen their lockup periods come and go. It is often common for new companies to price a secondary offering of additional shares six months to a year after the IPO, so traders may want to keep an eye out for those offerings.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.